Research Knowledgebase

Molecular Therapeutics Program

Program Leader(s)

For a list of all the program participants and related research, click here.

Description of Program

The principal aim of the Molecular Therapeutics Program is to promote, support, and accelerate translational research to expedite the development of rationally designed emerging cancer therapies based on pre-clinical research conducted in program members' laboratories. The ultimate goal is to improve cure rates and decrease morbidity and mortality for cancer patients by developing individualized targeted molecular cancer therapies.

Goals of Program

The Molecular Therapeutics Program's specific goals include:

• Delineate signal transduction pathways critical for cancer cell proliferation and survival leading to the identification and validation of novel molecular targets within these pathways.
• Discovery, development and design of biological and drug based therapies targeted for tumor specific individualized therapies.
• Bridge molecular discoveries from the bench to the clinic by translating intra-and inter-programmatic hypotheses-driven strategies into early phase I and II clinical trials.

Participants

Lynn G. Feun, M.D.
John Goldberg, M.D.
James Grichnik, M.D., Ph.D.
Thomas K. Harris, Ph.D.
Theodore Lampidis, Ph.D.
Zhao-Jun Liu, M.D., Ph.D.
Jaime R. Merchan, M.D., MMSc.
Enrique A. Mesri, Ph.D.
Abdul Moshin Mian, Ph.D.
Carlos T. Moraes, Ph.D.
Timothy Murray, M.D.
Dao M. Nguyen, M.D.
Mark D. Pegram, M.D.
Luis E. Raez, M.D., F.A.C.P.
Caio Max S. Rocha Lima, M.D.
Niramol Savaraj, M.D.
Andrew V. Schally, Ph.D., M.D.h.c., D.Sc.h.c.
Omaida Velazquez, M.D.
Teresa A. Zimmers-Koniaris, Ph.D.

Back to Research Knowledgebase